Misexpression and intracellular retention of peripheral myelin protein 22 (PMP22) is associated with hereditary neuropathies in humans, including Charcot-Marie-Tooth disease type 1A (CMT1A). Mice expressing extra copies of the human PMP22, termed C22, display morphologic and behavioral characteristics of CMT1A. In neuropathic Schwann cells, the turnover of the newly-synthesized PMP22 is decreased, leading to the formation of cytosolic protein aggregates. To aid the processing of PMP22 and alleviate the associated myelin defects, we pharmacologically stimulated the expression of protein chaperones by synthetic small-molecule inhibitors of heat shock protein 90 (HSP90). The exposure of Schwann cells to these compounds enhanced the levels of cytosolic chaperones in a time-and dosedependent manner, with minimal cytotoxicity. Treatment of dorsal root ganglion (DRG) explants from neuropathic mice improved myelin formation and the processing of PMP22. These results warrant further studies with HSP90 inhibitors as potential therapeutic candidates for hereditary demyelinating neuropathies.
Introduction
Hereditary peripheral neuropathies comprise a heterogeneous group of disorders, among which Charcot-Marie-Tooth disease type 1A (CMT1A) is the most prevalent form (Shy et al., 2001) . CMT1A is a demyelinating neuropathy mainly associated with a 1.5-megabase duplication on human chromosome 17 that includes the peripheral myelin protein 22 (PMP22) locus (Lupski et al., 1991) . Transgenic rodent models based on the overexpression of the wild type (Wt) PMP22 reproduce features of the human condition and provide experimental models to study disease pathogenesis (Huxley et al., 1996; Magyar et al., 1996; Sereda et al., 1996; Perea et al., 2001; Robertson et al., 2002) . One of these transgenic lines termed C22, express approximately 1.7-fold higher levels of the PMP22 mRNA and display slowed nerve conduction velocities and a reduction in the percentage of myelinated fibers (Huxley et al., 1996 (Huxley et al., , 1998 Robertson et al., 1999 Robertson et al., , 2002 .
Eukaryotic cells maintain protein homeostasis by using a collection of quality control pathways known as the unfolded protein response (UPR). Induction of UPR leads to the attenuated protein translation in the ER, ER-assisted folding and ER-associated degradation (ERAD) via the proteasome (Kincaid and Cooper, 2007) . PMP22 folds with only a modest efficiency even under normal conditions (Sanders et al., 2001) , as approximately eighty percent of the newly-synthesized protein is degraded by the proteasome (Pareek et al., 1997; Notterpek et al., 1999) . In response to PMP22 overexpression, the quality control system appears to be overwhelmed and protein aggregates form. In the C22 mouse model, a reduced turnover of the newly-synthesized PMP22 is associated with the presence of cytosolic protein aggregates within Schwann cells (SCs) and impaired proteasome activity (Fortun et al., 2006) . In myelinating dorsal root ganglion (DRG) explant cultures, the retention of PMP22 within the SC cytosol decreases the amount of protein at the plasma membrane (Fortun et al., 2006) , which could contribute to the observed myelin defects in affected mice.
A promising therapeutic approach for protein misfolding disorders, such as PMP22-associated neuropathies, involves the enhancement of chaperone expression (Muchowski and Wacker, 2005) . Inhibitors of heat shock protein 90 (HSP90), including geldanamycin (GA) and its pharmacologically improved derivatives, 17-DMAG and 17-AAG, have been shown to suppress aggregation of mutant huntingtin and α-synuclein in cultured cells (Nixon et al., 1994; Sittler et al., 2001; McLean et al., 2004; Herbst and Wanker, 2007 
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